Fundz

Immune Onc Therapeutics, Inc. reported raising $7 Million in an initial SEC Form D filing, from an offering of $7 Million

PRIVATESep 21, 2016

Amount Raised

$7 Million

$7 Million sold, per SEC Form D (first sale Sep 21, 2016)

Round Type

Venture

Palo AltoBiotechnologyHealth CareTherapeutics

Quick answer

Immune-Onc Therapeutics raised $7 Million in a funding round, dated September 21, 2016. Immune-Onc Therapeutics is based in Palo Alto, California, United States.

How much did Immune-Onc Therapeutics raise?
Immune-Onc Therapeutics raised $7 Million in a funding round on September 21, 2016.
What does Immune-Onc Therapeutics do?
Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.
Where is Immune-Onc Therapeutics based and how big is it?
Immune-Onc Therapeutics is based in Palo Alto, California, United States.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Immune-Onc Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Crispr Therapeutics raised $35M on November 4, 2016.
  • BioCardia raised $36M on November 4, 2016.
  • TuHURA Biosciences raised an undisclosed amount on November 4, 2016.
  • BIOVIE INC. raised $10K (Pre-Seed) on October 26, 2016.
  • Mustang Bio raised $12M on October 17, 2016.
  • Ocugen raised $30M on October 12, 2016.

Who to call at Immune-Onc Therapeutics, and when

A new round usually means Immune-Onc Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Immune-Onc Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Immune-Onc Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Immune-Onc Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Immune-Onc Therapeutics

Location

Palo Alto, California, United States

About

Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that reverse immune suppression in the tumor microenvironment. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (bi-specific antibody targeting LILRB4), and multiple undisclosed programs for solid tumors and hematologic malignancies. Immune-Onc has established agreements with leading biopharmaceutical companies, including BeiGene and Regeneron, to support its global product development plans for IO-108 and IO-202. It has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biopharmaceutical companies. For more information, please visit www.immune-onc.com and follow us on Twitter and LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Immune-Onc Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Immune-Onc Therapeutics's next move

See what Strategic adds

Immune-Onc Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.